Traduction de «drug administration » (Anglais → Français) :

Food and Drug Administration | United States Food and Drug Administration | US Food and Drug Administration | FDA [Abbr.] | US FDA [Abbr.]

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include self-report data, analysis of blood and other body fluids, characteristic physical and psychological symptom ...[+++]s, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

FDA | regulation of drug administration | drug administration regulations | regulations on drug administration

Drug Enforcement Administration [ DEA | Bureau of Narcotics and Dangerous Drugs | Bureau of Narcotics | Bureau of Drug Abuse Control ]

fetal distress in labour or delivery due to drug administration

EU Action Plan on Drugs | EU Action Plan to Combat Drugs | EU Drugs Action Plan | European Union Action Plan on Drugs | European Union Action Plan to Combat Drugs | European Union Drugs Action Plan

Drug Enforcement Administration | DEA [Abbr.]

execute workplace drug policies | prohibit drug and alcohol use in the workplace | enforce workplace drug policies | implement workplace drug policies

conducting of drug and alcohol abuse tests | drug abuse tests conduct | conduct drug abuse tests | conducting of drug abuse tests

accidental overdose of drug, wrong drug given or taken in error, and drug taken inadvertently accidents in the use of drugs, medicaments and biological substances in medical and surgical procedures (self-inflicted) poisoning, when not specified whether accidental or with intent to harm. Follow legal rulings when available (see note at Y10-Y34).

The Belarus, Ukraine, Moldova anti-drug programme (BUMAD) aims at strengthening the legal and administrative structures and to support these countries' efforts to combat drug trafficking.

(12) Encourages the Member States, in the light of their national legislation and administrative structures, to consider whether they should set up a national coordination mechanism or reinforce it if it already exists, and/or whether to designate a national drugs coordinator; [21]

(1) Considers that both national and European drugs coordination should be strengthened in the light of national legislation and traditions and administrative structures.

iii) the Council, acting on the basis of national legislation and administrative structures, to encourage all Member States to consider to establish where it does not exist and otherwise to strengthen the national coordination mechanism and/or to appoint a national drugs coordinator. [5]